PT2649075T - Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase - Google Patents

Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase

Info

Publication number
PT2649075T
PT2649075T PT118107143T PT11810714T PT2649075T PT 2649075 T PT2649075 T PT 2649075T PT 118107143 T PT118107143 T PT 118107143T PT 11810714 T PT11810714 T PT 11810714T PT 2649075 T PT2649075 T PT 2649075T
Authority
PT
Portugal
Prior art keywords
substituted pyrazolopyrimidines
glucocerebrosidase
activators
glucocerebrosidase activators
pyrazolopyrimidines
Prior art date
Application number
PT118107143T
Other languages
English (en)
Inventor
Jose Marugan Juan
Southall Noel
Goldin Ehud
Patnaik Samarjit
Sidransky Ellen
Motabar Omid
Westbrook Wendy
Zheng Wei
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of PT2649075T publication Critical patent/PT2649075T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT118107143T 2010-12-08 2011-12-08 Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase PT2649075T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42094610P 2010-12-08 2010-12-08

Publications (1)

Publication Number Publication Date
PT2649075T true PT2649075T (pt) 2018-07-30

Family

ID=45498099

Family Applications (2)

Application Number Title Priority Date Filing Date
PT118107143T PT2649075T (pt) 2010-12-08 2011-12-08 Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase
PT181650052T PT3366688T (pt) 2010-12-08 2011-12-08 Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT181650052T PT3366688T (pt) 2010-12-08 2011-12-08 Pirazolopirimidinas substituídas como ativadores de glucocerebrosidase

Country Status (23)

Country Link
US (3) US9353117B2 (pt)
EP (2) EP2649075B1 (pt)
JP (1) JP6154746B2 (pt)
KR (1) KR101931224B1 (pt)
CN (1) CN103534255B (pt)
AU (1) AU2011338377B2 (pt)
BR (1) BR112013014242B1 (pt)
CA (1) CA2820362C (pt)
DK (2) DK3366688T3 (pt)
ES (2) ES2681218T3 (pt)
HR (1) HRP20220512T1 (pt)
HU (1) HUE038635T2 (pt)
IL (2) IL226767B (pt)
LT (1) LT3366688T (pt)
MX (1) MX354506B (pt)
PL (2) PL3366688T3 (pt)
PT (2) PT2649075T (pt)
RS (1) RS63320B1 (pt)
RU (1) RU2603637C2 (pt)
SI (2) SI3366688T1 (pt)
TR (1) TR201810523T4 (pt)
WO (1) WO2012078855A1 (pt)
ZA (1) ZA201304215B (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3366688T3 (pl) 2010-12-08 2022-05-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
CN103764166B (zh) * 2011-06-22 2017-10-24 通用医疗公司 蛋白质病的治疗
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
CN103906733A (zh) 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
MX2013015058A (es) 2011-06-24 2014-01-20 Amgen Inc Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos.
AU2012325909B2 (en) * 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3077397T (pt) 2013-12-06 2020-01-22 Vertex Pharma Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
RS60013B1 (sr) 2014-06-05 2020-04-30 Vertex Pharma Radioaktivno obeleženi derivati jedinjenja 2-amino-6-fluoro-n-[5-fluoropiridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida, korisnog kao inhibitora atr kinaze, dobijanje pomenutog jedinjenja i njegovi različiti čvrsti oblici
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10118930B2 (en) 2014-11-03 2018-11-06 Bayer Pharma Aktiengesellschaft Piperidinylpyrazolopyrimidinones and their use
AU2015342883B2 (en) * 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
MX2017005940A (es) * 2014-11-06 2018-01-11 Lysosomal Therapeutics Inc Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
JP2018522872A (ja) * 2015-07-01 2018-08-16 ノースウェスタン ユニバーシティ 置換4−メチルピロロ[1,2−a]ピリミジン−8−カルボキサミド化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
EP3344632A4 (en) * 2015-09-04 2019-03-20 Lysosomal Therapeutics Inc. Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
WO2017040879A1 (en) * 2015-09-04 2017-03-09 Lysosomal Therapeutics Inc. Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2017161137A1 (en) * 2016-03-16 2017-09-21 Lysosomal Therapeutics Inc. Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
CA3020310A1 (en) * 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
MX2018013529A (es) * 2016-05-05 2019-07-04 Lysosomal Therapeutics Inc Imidazo[1,2-b]piridazinas sustituidas, imidazo[1,5-b]piridazinas sustituidas, compuestos relacionados y su uso en el tratamiento de trastornos médicos.
WO2017192929A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7059268B2 (ja) * 2016-11-02 2022-04-25 エフ.ホフマン-ラ ロシュ アーゲー IRAK4モデュレーターとしてのピラゾロ[1,5a]ピリミジン誘導体
PT3658557T (pt) * 2017-07-28 2024-09-11 Nimbus Lakshmi Inc Inibidores de tyk2 e usos dos mesmos
BR112020003725A2 (pt) 2017-10-06 2020-11-03 Forma Therapeutics, Inc. inibição da peptidase 30 específica de ubiquitina
WO2019151269A1 (ja) 2018-01-31 2019-08-08 武田薬品工業株式会社 複素環化合物
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物
US10882865B2 (en) 2018-08-31 2021-01-05 Northwestern University Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
JP7179161B2 (ja) 2018-09-10 2022-11-28 イーライ リリー アンド カンパニー 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ[1,5-a]ピリミジン-3-カルボキサミド誘導体
SI3860989T1 (sl) 2018-10-05 2023-06-30 Forma Therapeutics, Inc. Kondenzirani pirolini,ki delujejo kot zaviralci ubikvitin-specifične proteaze (usp30)
EP3866789A4 (en) * 2018-10-15 2022-07-06 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
EP4017593A1 (en) * 2019-08-21 2022-06-29 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
US20220380314A1 (en) 2019-09-17 2022-12-01 Bial - R&D Investments, S.A. Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
KR20220100859A (ko) 2019-09-17 2022-07-18 비알 - 알&디 인베스트먼츠, 에스.에이. 산성 세라미다아제 저해제로서의 치환된 n-헤테로시클릭 카르복사미드, 및 약제로서의 이의 용도
BR112022004791A2 (pt) 2019-09-17 2022-06-21 Bial R&D Invest S A Carboxamidas de imidazol substituídas e seu uso no tratamento de distúrbios médicos
AR121251A1 (es) 2020-02-12 2022-05-04 Lilly Co Eli Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003284886A1 (en) 2002-10-21 2004-05-13 William E. Balch CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF Beta-GLUCOSIDASE
JP2004277337A (ja) * 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ[1,5−a]ピリミジン誘導体
WO2004089471A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
AU2004289327A1 (en) 2003-11-12 2005-05-26 Amicus Therapeutics Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease
CA2507348C (en) 2004-05-13 2013-07-16 The Hospital For Sick Children Real time methylumbelliferone-based assay
ATE396725T1 (de) * 2004-05-14 2008-06-15 Cleveland Clinic Foundation Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter
RU2378277C2 (ru) 2004-06-21 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные пиразолпиримидина
DE102005007534A1 (de) * 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
US20070155737A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
EA013525B1 (ru) 2005-05-20 2010-06-30 Алантос-Фармасьютикалз Холдинг, Инк. Гетеробициклические ингибиторы металлопротеазы и их применение
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
JP4987871B2 (ja) * 2005-08-15 2012-07-25 エフ.ホフマン−ラ ロシュ アーゲー P2x3アンタゴニストとしてのピペリジン及びピペラジン誘導体
AR056876A1 (es) * 2005-10-21 2007-10-31 Tanabe Seiyaku Co Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares
CA2626742A1 (en) * 2005-10-21 2007-04-26 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
WO2008054947A2 (en) 2006-10-02 2008-05-08 The Brigham And Women's Hospital, Inc. Structure of acid beta-glucosidase and methods for identifying therapeutic agents
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
WO2008063671A2 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
JP5586453B2 (ja) 2007-04-13 2014-09-10 アミカス セラピューティックス インコーポレイテッド 特異的薬理シャペロンによるゴーシェ病の治療および代理マーカーを用いた治療の監視
WO2008134036A1 (en) 2007-04-27 2008-11-06 Panacos Pharmaceuticals, Inc. ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES
US8454954B2 (en) 2007-05-16 2013-06-04 The Brigham And Women's Hospital, Inc. Treatment of synucleinopathies
US20090118135A1 (en) 2007-06-08 2009-05-07 The Burnham Institute Methods and compounds for regulating apoptosis
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
WO2009049422A1 (en) 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN102112478A (zh) * 2008-06-10 2011-06-29 普莱希科公司 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
JP2011526925A (ja) * 2008-07-01 2011-10-20 ザカロン ファーマシューティカルズ,インク. ヘパラン硫酸阻害剤
WO2010086040A1 (en) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
PL3366688T3 (pl) 2010-12-08 2022-05-23 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy
MX2017005940A (es) * 2014-11-06 2018-01-11 Lysosomal Therapeutics Inc Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.

Also Published As

Publication number Publication date
SI2649075T1 (sl) 2018-10-30
AU2011338377B2 (en) 2016-08-04
ES2912284T3 (es) 2022-05-25
ES2681218T3 (es) 2018-09-12
IL259648B (en) 2021-03-25
CN103534255A (zh) 2014-01-22
DK3366688T3 (da) 2022-05-02
SI3366688T1 (sl) 2022-07-29
US20180263988A1 (en) 2018-09-20
RS63320B1 (sr) 2022-07-29
HUE038635T2 (hu) 2018-11-28
BR112013014242B1 (pt) 2022-02-22
JP6154746B2 (ja) 2017-06-28
HRP20220512T1 (hr) 2022-05-27
CA2820362C (en) 2020-03-24
US20140249145A1 (en) 2014-09-04
EP2649075B1 (en) 2018-04-25
US20160346284A1 (en) 2016-12-01
WO2012078855A1 (en) 2012-06-14
KR20140010012A (ko) 2014-01-23
DK2649075T3 (en) 2018-07-30
RU2013126094A (ru) 2015-01-20
US10925874B2 (en) 2021-02-23
TR201810523T4 (tr) 2018-08-27
LT3366688T (lt) 2022-05-25
US9353117B2 (en) 2016-05-31
ZA201304215B (en) 2014-03-26
PL2649075T3 (pl) 2018-09-28
IL226767B (en) 2018-06-28
IL259648A (en) 2018-07-31
US9974789B2 (en) 2018-05-22
PL3366688T3 (pl) 2022-05-23
KR101931224B1 (ko) 2018-12-20
EP3366688B1 (en) 2022-02-09
RU2603637C2 (ru) 2016-11-27
PT3366688T (pt) 2022-05-11
EP2649075A1 (en) 2013-10-16
AU2011338377A1 (en) 2013-07-04
CN103534255B (zh) 2016-12-21
JP2013544893A (ja) 2013-12-19
MX354506B (es) 2018-01-16
AU2011338377A8 (en) 2015-10-29
CA2820362A1 (en) 2012-06-14
EP3366688A1 (en) 2018-08-29
BR112013014242A2 (pt) 2018-06-26
MX2013006462A (es) 2013-10-01

Similar Documents

Publication Publication Date Title
IL259648B (en) Pyrazolopyrimidines are metabolized as glucocerebrosidase enzymes
HK1182594A1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives n3--n1--5-
AP2013006790A0 (en) Substituted imidazopyradazines
ZA201209117B (en) Tetrahydro-pyrido-pyrimidine derivatives
EP2534256A4 (en) NEW USES
HK1190406A1 (zh) 雙環 激活劑
EP2543670A4 (en) PYRAZOLOPYRIMIDINE DERIVATIVE
AP3429A (en) Substituted sodium-1h-pyrazole-5-olate
EP2541164A4 (en) COOLER
GB2490849B (en) Di-aspirin derivatives
EP2603559A4 (en) POLYISOCYANURATE COMPOSITION
HUP1000243A2 (en) 8-hidroxy-quinoline derivatives
HK1174625A1 (en) Pyrrazolopyridine derivatives
IL225312A0 (en) New combinations
AU4538P (en) H22 Grevillea juniperina
ZA201209248B (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives
AU332681S (en) Spindle
GB201008355D0 (en) Solid supports
GB201019442D0 (en) Novel combinations
AU2010900285A0 (en) Sparger